Web Desk: Pakistan’s drug regulator has issued a nationwide safety alert after laboratory tests identified four counterfeit medicine samples that lacked their declared active ingredients, raising concerns about the risks posed to patients using the affected products.
The Drug Regulatory Authority of Pakistan (DRAP) issued the alert on October 21, 2026, following analysis by the Drug Testing Laboratory (DTL) in Karachi. The findings indicated that the tested samples did not contain the active pharmaceutical ingredients specified on their labels.
The affected products include Velosef 500mg Capsules, Augmentin 625mg Tablets, No-Spa Forte 80mg Tablets and Mucaine Suspension.
The laboratory findings have raised concerns about the quality and authenticity of the four products, as the absence of their declared active ingredients means patients may not receive the intended therapeutic benefits.
Counterfeit medicines can undermine treatment by failing to address the conditions for which doctors prescribe them. Moreover, patients who unknowingly use such products may experience delays in receiving effective treatment, potentially worsening their medical conditions.
The findings highlight the potential dangers of counterfeit medicines entering the pharmaceutical supply chain. Products that lack their stated active ingredients may fail to deliver the expected clinical effects, leaving patients without effective treatment.
Furthermore, counterfeit products can be difficult for consumers to identify because their packaging and labelling may resemble those of genuine medicines.
DRAP’s nationwide alert draws attention to the need for vigilance across the medicine supply chain, including among healthcare professionals, pharmacies, distributors and regulatory authorities.
Read more: Fact check: PTI social media caught spreading fake news about Murad Saeed’s family
